Literature DB >> 24982238

Inhibitory action of levocetirizine on the production of eosinophil chemoattractants RANTES and eotaxin in vitro and in vivo.

Ayako Kanei1, Kazuhito Asano2, Ken-Ichi Kanai1, Atsuko Furuta1, Keigo Sasaki3, Harumi Suzaki4.   

Abstract

Eosinophils are well known to play essential roles in the development and maintenance of allergic diseases. However, the influence of histamine H1 receptor antagonists on eosinophil functions, especially chemokine production, are not well-defined. Therefore, in the present study, we examined the influence of histamine H1 receptor antagonist on chemokine production by eosinophils through the use of levocetirizine in vitro and in vivo. Eosinophils prepared from mice were stimulated with specific antigens in the presence of different concentrations of levocetirizine. After 24 h, regulated on activation normal T cell expressed and secreted (RANTES) and eotaxin levels in culture supernatants were measured by enzyme-linked immunosorbent assay (ELISA). Patients with Japanese cedar pollinosis were treated with 5 mg levocetirizine once a day for four weeks during the pollen season (February 2012 to April 2012). RANTES and eotaxin levels in nasal secretions were also examined by ELISA. The addition of levocetirizine to eosinophil cultures caused a dose-dependent decrease in the ability of cells to produce RANTES and eotaxin in response to antigen stimulation, and the minimum concentration that caused a significant decrease was 0.05 μM. Although cetirizine also exerted suppressive effects on the production of RANTES and eotaxin by eosinophils, the minimum concentration that caused significant suppression was 0.15 μM, which was three-times higher than that of levocetirizine. Oral administration of levocetirizine for four weeks also reduced RANTES and eotaxin levels in nasal secretions from patients with pollinosis, along with attenuation of clinical symptoms. The ability of levocetirizine to reduce RANTES and eotaxin levels may account, at least in part, for the clinical efficacy of the agent for allergic disorders, including allergic rhinitis.
Copyright © 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Eotaxin; RANTES; allergic rhinitis; eosinophil; levocetirizine; nasal secretion; production; suppression

Mesh:

Substances:

Year:  2014        PMID: 24982238

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  2 in total

1.  Expression of eosinophils, RANTES and IL-25 in the first phase of Hymenoptera venom immunotherapy.

Authors:  Krzysztof Pałgan; Magdalena Żbikowska-Götz; Zbigniew Bartuzi
Journal:  Postepy Dermatol Alergol       Date:  2019-04-01       Impact factor: 1.837

2.  Repurposing levocetirizine hydrochloride loaded into cationic ceramide/phospholipid composite (CCPCs) for management of alopecia: central composite design optimization, in- silico and in-vivo studies.

Authors:  Rofida Albash; Rania Moataz El-Dahmy; Mohammed I A Hamed; Khaled M Darwish; Abdulrahman M Alahdal; Amira B Kassem; Abdurrahman M Fahmy
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.